Biotinylated Human TRAIL R4/TNFRSF10D Protein
Catalog No: TNFRSF10D-HB001
- Species
- Human
- Expression System
- HEK293
- Tag
- His, Avi
- Activity
- Activity verified
Product overview
Recombinant Biotinylated Human TRAIL R4/TNFRSF10D Protein is expressed in HEK293 cells with a His tag and Avi tag at the C-terminus. It contains amino acid residues Ala56-His211 (UniProt accession: Q9UBN6).
Product Details
- Molecular Aliases
- CD264; RSF10D; TRAILR4; DCR2; TRUNDD; TNFRSF10D
- Protein Length
- Ala56-His211
- Expression System
- HEK293
- Theoretical Molecular Weight
- The protein has a predicted MW of 19.4 kDa. Due to glycosylation, the protein migrates to 38-50 kDa based on Bis-Tris PAGE result.
- Purity
- > 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC
- Endotoxin
- Less than 1 EU per μg by the LAL method.
- Buffer / Formulation
- Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
- State
- Lyophilized
- Storage Conditions
- -20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
- Reconstitution Advice
- Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions.
Data Display
Biotinylated Human TRAIL R4 on Bis-Tris PAGE under reduced conditions. The purity is greater than 95%.
The purity of Biotinylated Human TRAIL R4 is greater than 95% as determined by SEC-HPLC.
Immobilized Human TRAIL, No Tag at 5μg/ml (100μl/well) on the plate. Dose response curve for Biotinylated Human TRAIL R4, His Tag with the EC50 of 0.14μg/ml determined by ELISA (QC Test).
Biotinylated Human TRAIL R4, His-Avi tag immobilized on CM5 Chip can bind Human TRAIL, No Tag with an affinity constant of 0.135 nM as determined in SPR assay (Biacore T200).
Background
TNF-related apoptosis inducing ligand (TRAIL) is a potential antitumor protein known for its ability to selectively eliminate various types of tumor cells without exerting toxic effects in normal cells and tissues. TRAIL-R2/DR5 as well as TRAIL-R3/DcR1 and TRAIL-R4/DcR2 were significantly higher expressed in advanced tumour stages.
References
- Werner TA, Nolten I, Dizdar L, Riemer JC, Schütte SC, Verde PE, Raba K, Schott M, Knoefel WT, Krieg A. IAPs cause resistance to TRAIL-dependent apoptosis in follicular thyroid cancer. Endocr Relat Cancer. 2018 Mar;25(3):295-308. doi: 10.1530/ERC-17-0479. Epub 2018 Jan 9. PMID: 29317481.
Have questions about this product?
Our technical team can help with product selection, application questions and order support.